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Background: Accumulating evidences have identified the immunoregulatory features of stem cells. In this study,
the immunoregulation of bone marrow-derived stem cells (BMSCs) transplanted into patients with HBV-related
decompensated cirrhosis and mouse model of liver injury induced by carbon tetrachloride (CCl4) administration
was observed.
Results: Compared with healthy controls, patients with HBV-related decompensated cirrhosis showed significantly
higher levels of TNF-alpha, IL-12, TGF-beta1, IL-17, and IL-8. However, only IL-17 was markedly decreased after
autologous BMSCs transplantation during their follow-up. The same results were found in the CCl4-treated mice.
Furthermore, we found that exogenous IL-17 partly abolished the therapeutic effect of BMSCs whereas
IL-17-specific antibody promoted improvement of liver injury in CCl4-treated mice, resembling the therapeutic
effect of BMSCs transplantation.
Conclusions: These data suggested that BMSCs transplantation induces a decrease of IL-17 level, which at least in
part delineates the mechanisms of stem cells-mediated therapeutic benefit on liver disease.
Keywords: Bone marrow-derived stem cells, Decompensated cirrhosis, IL-17, Immunoregulation, HBV, Carbon
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More recently, advances in the understanding of bone
marrow-derived stem cells (BMSCs) biology and plasti-
city have raised hopes that stem cell therapy may offer
exciting therapeutic possibilities for patients with liver
diseases [1,2]. However, there is much debate concerning
the mechanisms by which BMSCs contribute to hepatic
regeneration. Recently, more and more evidence have
identified the strong immunoregulatory effect of stem
cells [3,4].
It is well known that inflammation is a critical factor
in the initiation and maintenance of liver fibrogenesis.
When liver injuries occur, damaged epithelial and/or
endothelial cells release inflammatory mediators that re-
cruit peripheral blood inflammatory cells to the damaged* Correspondence: hanying1@fmmu.edu.cn
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reproduction in any medium, provided the orliver and release of fibrosis-related mediators including
TGF-beta1 and TNF-alpha, triggering activation of hep-
atic stellate cells and formation of extracellular matrix
[5]. Recently, some reports suggest that proinflammatory
cytokine IL-17 (also known as IL-17A) plays an import-
ant role in many liver diseases, including alcoholic liver
disease, hepatocellular carcinoma, autoimmune liver dis-
ease, acute and chronic hepatitis B and it is associated
with the disease progression [6-9]. Cytokines, signaling pro-
teins produced by different kinds of cell types, are essential
for the development and function of both innate and adap-
tive immune response. However, the regulatory effect of
BMSCs on some kinds of cytokines is still obscure.
On the basis of previous studies, we initiated a clinical
study analyzing the regulation of BMSCs on several kinds
of cytokines after transplanting into HBV-related decom-
pensated cirrhotic patients. And then we verified our clin-
ical results using a well-estimated mouse model of carbon
tetrachloride (CCl4)-induced liver injury and we firstly
found that the therapeutic effect of BMSCs was, at least in
part, due to their down-regulation of IL-17.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therapeutic effect of autologous BMSCs transplantation
on patients with HBV-related decompensated cirrhosis
Data for serum albumin (ALB), prothrombin activity
(PTA), and cholinesterase (CHE) were collected from the
enrolled patients at baseline (1 week before transplant-
ation), and at 4, 12, 24, 36 and 48 weeks after BMSCs
transplantation, respectively. As shown in Table 1, com-
pared with baseline, the average levels of serum ALB, PTA
and CHE had markedly increased at 4 weeks after trans-
plantation. And Child-Turcotte- Pugh (CTP) and Model
for End-Stage Liver Disease (MELD) scores were gradually
decreased and reached statistical difference at 4 weeks. No
serious adverse effect was observed after transplantation.
Decrease of serum IL-17 after autologous BMSCs
transplantation in patients
The results showed that serum TNF-alpha, IL-12, TGF-
beta1, IL-17, and IL-8 in HBV-related decompensated
cirrhotic patients were significantly higher than that in
age- and sex-matched healthy controls. But the changes
of IFN-gamma and IL-13 displayed no statistical signifi-
cance (Table 2). IL-4 was below the assay detection limit
and was not detectable both in patients and in healthy
controls. Then we examined the changes of the afore-
mentioned cytokines in patients after BMSCs transplant-
ation during entire follow-up. As shown in Table 2,
compared with baseline, only IL-17 was found to be sig-
nificantly decreased at 24 weeks after BMSCs transplant-
ation (p < 0.01), and kept on declining through the entire
follow-up. Interestingly, there was a close relationship
between serum IL-17 and liver function. A highly negative
correlation was observed between serum IL-17 and ALB
(r = −0.884, p = 0.019), but a positive correlation existed be-
tween serum IL-17 and MELD score (r = 0.927, p = 0.008)
(Figure 1).
Change of IL-17 in mouse model of liver injury induced
by CCl4 injection
CCl4 injection to mice for 6 weeks resulted in overt but
reversible liver injury. As shown in Figure 2, afterTable 1 Improved liver function of patients after bone marro
Index
Baseline 4w 12w
Albumin(g/L) 29.25(3.80) 34.83(4.87)* 35.98(4.36)*
PTA(%) 51.50(15.51) 61.46(17.80)* 64.23(13.45)*
CHE(U/L) 2766.43(913.79) 3527.94(1113.25)* 3625.55(1150.
CTP score 9.05(1.94) 7.25(1.98)* 7.03(2.16)*
MELD score 14.04(4.89) 12.09(3.31)* 11.33(4.60)*
Values are expressed as the mean (standard deviation).
*p < 0.05 in comparison with baseline. Baseline, 1 week before transplantation.
PTA, prothrombin activity; CHE, cholinesterase; CTP, Child-Turcotte-Pugh; MELD, Morepeatedly 6-week CCl4 injection, when compared with
oil-treated controls, hematoxylin and eosin (H&E) and
Sirius red staining showed a visible inflammation and fi-
brosis. And serum ALB declined statistically. The expres-
sions of alpha- smooth muscle actin (SMA) and collagen-1
mRNA in liver tissues measured by real time-polymerase
chain reaction (RT-PCR) significantly increased. However,
the aforementioned changes were gradually reversed to
nearly normal levels after 4 weeks stopped CCl4 injection
(Figure 2).
Then we measured the dynamic changes of IL-17 in
the pathogenesis of mouse liver injury induced by CCl4
injection. Statistically, serum IL-17 level increased sig-
nificantly during 6-week CCl4 administration, but then
gradually decreased after 4 weeks of stopped CCl4 injec-
tion compared with oil treated control (Figure 3). This
indicates a closed relationship between IL-17 level and
severity of liver injury.
A causative role of IL-17 in the pathogenesis of liver
injury in mice
To investigate whether IL-17 has a causative effect in
the CCl4-induced liver injury, we changed IL-17 level
in vivo by administration of exogenous recombinant mouse
(rm) IL-17 or blockade of endogenous IL-17 with neutral-
izing IL-17-specific antibody (anti-IL-17 mAb). H&E and
Sirius red staining showed that liver inflammation and
fibrosis were significantly exacerbated by injection of rmIL-
17, but ameliorated by neutralizing anti-IL-17 mAb com-
pared with only CCl4 injection group (Figure 4A, B). The
serum ALB in only CCl4 group was higher than that in
rmIL-17 group, but significantly lower than that in anti-
IL-17 mAb group (Figure 4C). Similarly, RT-PCR ana-
lysis confirmed that the hepatic mRNA expressions of
alpha-SMA and collagen-1 were significantly increased
in rmIL-17 injected group, but markedly decreased in
anti-IL-17mAb treated mice compared with controls
(Figure 4D, E). IL-17 levels were significantly increased
in rmIL-17-injected group, but decreased in anti-IL-17
mAb-treated group compared with control groups (data





36)* 4168.91(1403.57)* 4438.27(1032.26)* 4902.87(1771.91)*
6.45(1.60)* 6.52(1.93)* 6.64(1.69)*
10.34(4.93)* 10.40(4.09)* 10.52(6.36)*
del for End-Stage Liver Disease.
Table 2 Dynamic changes of cytokines after bone marrow-derived stem cells (BMSCs) transplantation
Cytokines HC Weeks after BMSCs transplantation
Baseline 4w 12w 24w 36w 48w
TNF-α 1.8(1.2) 36.2(7.6)a 34.1(12.3) 38.3(9.2) 32.4(5.3) 31.6(2.5) 32.5(5.7)
IFN-γ 3.0(1.1) 2.0(0.8) 4.5(1.3) 1.0(0.7) 1.7(0.8) 2.6(0.4) 3.7(1.1)
IL-12 3.2(0.6) 23.2(1.4)a 21.4(2.1) 18.9(1.7) 20.1(2.2) 19.6(1.5) 20.5(1.2)
IL-13 5.6(1.4) 5.7(2.0) 6.1(1.2) 7.5(2.1) 6.0(1.5) 5.8(1.2) 5.7(1.5)
TGF-β1 8.9(1.3) 23.4(8.3)a 26.5(7.6) 18.2(6.2) 21.6(3.7) 19.5(9.1) 22.2(4.3)
IL-17 21.2(18.9) 216.4(109.3)a 269.8(112.4) 189.0(108.2) 106.1(92.3)b 118.2(102.9)b 57.0(32.7)b
IL-8 17.2(10.3) 131.4(59.3)a 142.9(71.5) 129.3(50.2) 150.2(48.2) 136.5(32.7) 132.4(70.2)
Values are expressed as the mean (standard deviation).
ap<0.05 in comparison with HC; bp<0.05 in comparison with Baseline.
HC, healthy controls; Baseline, 1 week before transplantation.
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injury and down-regulates IL-17 level in mice
Transplantation of BMSCs to CCl4-treated mice signifi-
cantly improved not only liver function, but also liver fi-
brosis. As shown in Figure 5A and B, H&E and Sirius
red staining showed that liver inflammation and fibrosis
were significantly ameliorated after BMSCs transplant-
ation. Compared with CCl4-treated control, serum ALB
in BMSCs-transplanted mice increased statistically, and
the expressions of alpha-SMA and collagen-1 mRNA in
liver tissues significantly declined (Figure 5C-E). Strikingly,
serum IL-17 decreased markedly after BMSCs transplant-
ation compared control (Figure 5F).
IL-17 is a key for BMSCs-mediated amelioration of liver
injury in mice
In an attempt to determine whether decrease of IL-17
levels could be linked to the therapeutic benefits of
BMSCs transplantation on CCl4-induced liver injury, the
6-week CCl4-treate mice were randomly divided into
several groups as described in the Material and Methods
part. As shown in Figure 5, H&E and Sirius red staining
showed that the areas of liver fibrosis in BMSCs and
anti-IL-17 mAb groups were significant decreased than
that in only CCl4-treated group. However, there was no
significant difference between BMSCs and Anti-IL-17Figure 1 Relationships between IL-17 level and liver function in patie
(B) were calculated using the Spearman rank correlation test. The solid line
ALB, albumin; MELD score, Model for End-Stage Liver Disease score.mAb groups. Meanwhile, the area of liver fibrosis in
rmIL-17 group was markedly increased than that in only
CCl4-treated or BMSCs groups. Strikingly, the difference
in the area of liver fibrosis between BMSCs and rmIL-
17 + BMSCs groups was overt (p < 0.05). These results
were confirmed by the hepatic mRNA expressions of
alpha-SMA and collagen-1 in liver tissues. Moreover,
serum ALB in BMSCs and anti-IL-17 mAb groups was
significant higher than that in only CCl4-treated group.
And there was no significant difference between BMSCs
and Anti-IL-17 mAb groups. Serum ALB in rmIL-17 +
BMSCs group displayed significantly lower than that in
BMSCs group, indicating exogenous IL-17 could block
the therapeutic effect of BMSCs.
Discussion
More recently, the therapeutic effect of stem cell trans-
plantation on liver diseases have been investigated in
mice and human, yet the underlying mechanisms are
obscure. The present study demonstrates that trans-
plantation of autologous BMSCs could down-regulate
serum IL-17 in patients with HBV-related decompen-
sated cirrhosis and in mouse model of CCl4-induced
liver injury, which may at least partly delineate the
mechanisms of BMSCs-mediated therapeutic benefit on
liver diseases.nts. The relationships between IL-17 level and ALB (A) and MELD score
represents the linear growth trend, r means correlation coefficient.
Figure 2 Liver injury induced by CCl4 administration. The mice
were repeatedly treated with oil alone or CCl4 mixture for 6 weeks
to induce liver injury, and then stopped injection to observe
spontaneous recovery for 4 weeks. (A) Liver inflammatory (upper
panels arrowhead) and hepatic collagen deposition (lower panels
arrowhead) were determined by H&E and Sirius red staining. Original
magnifications: upper panels × 100, lower panels × 40. (B) The
percentage of stained red area of Sirius red was assessed at 100 ×
magnification with a quantitative image analyzer. (C) Serum
chemistry of liver function was performed for albumin (ALB). The
expressions of alpha- smooth muscle actin (SMA) (D) and collagen-1
(E) mRNA in liver tissues were measured by real time (RT)-PCR. CCl4
6w, 6-week CCl4 injection; Rec 4w, stopped CCl4 injection for 4-week
to recover spontaneously. *p < 0.05, **p < 0.01.
Figure 3 Change of IL-17 in the pathogenesis of mouse liver
injury induced by CCl4 injection. Solid line and dash line showing
the dynamic change of plasma IL-17 in the pathogenesis of mouse
liver injury induced by CCl4 injection. *p < 0.05, **p < 0.01 vs oil-
treated group. Start, the time when oil or CCl4 injection started;
Treat, oil or CCl4 treatment; Stop, stopped oil or CCl4 injection.
Figure 4 Key role of IL-17 in the pathogenesis of liver injury
induced by CCl4 injection. Before CCl4 injection, mice were given
monoclonal rat anti-mouse IL-17 antibody (anti-mouse IL-17 mAb)
or recombinant mouse (rm) IL-17. (A) Liver inflammatory (upper
panels arrowhead) and hepatic collagen deposition (lower panels
arrowhead) were determined by H&E and Sirius red staining. Original
magnifications: upper panels × 100, lower panels × 40. (B) The
percentage of stained red area of Sirius red was assessed at 100 ×
magnification with a quantitative image analyzer. (C) Serum chemistry
of liver function was performed for albumin (ALB). The expressions of
alpha- smooth muscle actin (SMA) (D) and collagen-1 (E) mRNA
in liver tissues were measured by real time (RT)-PCR.
*p < 0.05, **p < 0.01.
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from bone marrow including mesenchymal stem cells
(MSCs), hematopoietic stem cells (HSCs) and unsorted
mononuclear cells. However, which cell type is more
effective in treating liver diseases is largely unknown. Re-
cently, several studies have suggested that MSCs and
HSCs function synergistically for the therapy of diabetes
and heart failure [10,11]. The rationale for the synergis-
tic actions of MSCs and HSCs may be that MSCs pro-
vide a microenvironment for HSCs in both embryonic
and postnatal stage [12]. Thus, the mixture of bone mar-
row stem cells was used in our study.
Consistent with previous reports [2,13,14], we demon-
strated that most HBV-related decompensated cirrhotic
patients with BMSCs transplantation displayed signifi-
cantly improved liver function during 48 weeks of follow-
up. As shown in Table 1, signs of clinical improvement of
liver function, ALB, PTA, CHE, CTP and MELD scores,
were observed after transplantation. And the peak of
Figure 5 IL-17 is a key for BMSCs-mediated amelioration of
liver injury induced by CCl4 injection. After 6 weeks of CCl4
administration to induced liver injury, the mice were randomly
divided into several groups and were given a tail vein injection of
BMSCs (5 × 106 cells in 0.2 ml PBS), a intraperitoneal injection of
rmIL-17, a intraperitoneal injection of rmIL-17 and a tail vein injection
of BMSCs, and five intraperitoneal injections of anti-mouse IL-17
mAb, respectively. Then the mice continued to be given CCl4
injection during our study to maintain liver fibrotic status. One group
mice were only given CCl4 injection during the whole study and
served as control. (A) Liver inflammatory (upper panels arrowhead)
and hepatic collagen deposition (lower panels arrowhead) were
determined by H&E and Sirius red staining. Original magnifications:
left panels × 100, right panels × 40. (B) The percentage of stained
red area of Sirius red was assessed at 100 ×magnification with a
quantitative image analyzer. (C) Serum chemistry of liver function
was performed for albumin (ALB). The expressions of alpha- smooth
muscle actin (SMA) (D) and collagen-1 (E) mRNA in liver tissues were
measured by real time (RT)-PCR. (F) The plasma IL-17 level was
analyzed by enzyme-linked immunosorbent assay (ELISA). Results
represent means and standard deviation (SD) of at least five mice
per group. BMSCs, bone marrow-derived stem cells.
*p < 0.05, **p < 0.01.
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sidering the high risk of liver biopsy in end-stage liver dis-
ease patients, we did not perform histological analysis.
These data suggest that BMSCs transplantation, at least in
short term, may be an effective and safe therapeutic ap-
proach for HBV-related decompensated cirrhosis.
With accumulating evidences about the implication of
inflammation in the pathogenesis of diseases, the immu-
noregulatory features of stem cells have drawn more at-
tention. It has been reported that MSCs could inhibit
the function of T-lymphocytes, natural killer (NK) cells
and dendritic cells, and regulate their cytokine spectrums,
showing an immunoregulatory capacity in vitro and in vivo
[15-17]. Recently, Suh et al. [18] investigated that bone
marrow cells have the capacity of anti-inflammation and
anti-fibrosis through expression of IL-10. And some stud-
ies have reported that MSCs can prevent naive CD4+ T
cells from differentiating into Th17 cells and inhibit the
production of IL-17 in vitro [19,20]. However, some other
studies indicate that co-culture of splenocytes and MSCs
in vitro could increase IL-17 secretion [21,22]. The oppos-
ite regulatory effect of MSCs on the production of IL-17
may be related to the different co-culture systems in vitro.
In vivo study, we found that serum IL-17 in patients with
HBV-related decompensated cirrhosis statistically de-
creased at 24 weeks after BMSCs transplantation when
compared with baseline. It is noteworthy that there was
a highly negative correlation between serum IL-17 and
ALB, but a positive correlation between serum IL-17
and MELD score. However, the other cytokines, afore-
mentioned, were not significantly changed after trans-
plantation. And in the mouse model of CCl4-induced
liver injury, IL-17 level also markedly declined after
transplantation of homologous BMSCs.
IL-17, produced by CD4+ Th17 cells, NKT cells, mast
cells, neutrophils and gamma delta T cells [23,24], plays
a major role in host protection against extracellular
pathogens and induction of tissue inflammation [25]. It
has been found that IL-17 plays a critical role in pul-
monary fibrosis [26] and psoriasis [27]. And some recent
clinical studies have been reported that utilization of
human anti-IL-17 monoclonal antibody [28] or human
anti-IL-17-receptor monoclonal antibody [29] could im-
prove clinical symptoms of psoriasis. And emerging evi-
dences have indicated that IL-17 is implicated in the
induction of liver injury and liver fibrosis both in human
and in mice [30,31]. Similarly, we found that not only
HBV-related decompensated cirrhotic patients, but also
mouse model of liver injury induced by CCl4 administra-
tion displayed significant higher serum IL-17 levels than
that in healthy controls. And in mice, a dynamic change
of IL-17 level was observed during the progression of
well-established CCl4-induced liver injury in mice. More-
over, the deteriorated effect of exogenous IL-17 and
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apparent during the procession of liver injury. Recent
study found that IL-17 induces liver injury and fibrosis
may through two mechanisms: IL-17 stimulates kupffer
cells to express other inflammatory cytokine, such as
TNF-alpha, and fibrogenic cytokine TGF-beta1; IL-17
directly stimulates hepatic stellate cells to express colla-
gen and promotes their activation into fibrogenic myofi-
broblast via Stat3 [30]. These results suggest that IL-17
has a strong profibrogenic effect in the pathogenesis of
liver disease and it is positively correlated with the se-
verity of liver injury. However, which cell type is the
main producer of IL-17 in the pathogenesis of liver in-
jury, and how IL-17 induces liver injury and fibrosis
need to be further pursued.
However, the question in our results is that we cannot
distinguish cause and effect. Was the down-regulation of
serum IL-17 a cause of the therapeutic effect of BMSCs on
patients/mice with liver diseases, or was merely a satellite
phenomenon? In the mouse model of CCl4-induced liver
injury, we found that blockage of endogenous IL-17 with
anti-IL-17-specific antibody could promote improvement
of liver injury, resembling the therapeutic effect of BMSCs
transplantation. It suggests that amelioration of liver injury
may be due to the down-regulation of IL-17 either by neu-
tralizing anti-IL-17 antibody or by BMSCs transplantation.
Furthermore, injection of exogenous rmIL-17 significantly
exacerbated liver injury, and even abolished the therapeutic
effect of BMSCs transplantation on CCl4-induced mouse
liver injury, indicating down-regulating IL-17 is a key
for BMSCs-mediated amelioration of hepatic injury in
mice. However, how BMSCs regulates IL-17 will be our
next studies.
It should admit the shortcomings in our study that the
mouse model of CCl4-induced liver injury, which has long
been used as a valuable model to investigate the patho-
physiological mechanism of liver injury and fibrosis, is
different from patients with HBV-related decompensated
cirrhosis. Therefore, it will be helpful in the future to
utilize two or more animal models to clarify the role of IL-
17 in the process of BMSCs-mediated amelioration of liver
diseases.
Conclusions
Here, we have shown that IL-17 increases significantly
in HBV-related decompensated cirrhotic patients and
CCl4-treated mice compare with controls. And a highly
negative correlation between IL-17 and liver function in-
deed exists. Moreover, the deteriorated effect of exogen-
ous IL-17 and protective effect of neutralizing anti-IL-17
antibody are apparent during the procession of CCl4-in-
duced liver injury in mice.
A marked decrease of IL-17 after BMSCs transplant-
ation in patients and CCl4-treated mice has been found.In animal study, it is demonstrated that exogenous IL-17
partly abolishes the therapeutic effect of BMSCs whereas
IL-17-specific antibody promotes improvement of liver
injury in CCl4-treated mice, resembling the therapeutic
effect of BMSCs transplantation.
Overall, we reveal a previously unrecognized finding
that BMSCs transplantation exerts their beneficial action





All 42 HBV-related decompensated cirrhotic patients re-
ceived mobilized BMSCs transplantation were hospital-
ized in Xijing Hospital from July 2009 to December
2010. Patients were included if they were 18–70 years of
age, with clinical, biochemical, sonograhpic, and histology
diagnosis of HBV-related decompensated liver cirrhosis.
Evidences of decompensated liver cirrhosis were at screen-
ing, such as portal hypertension, serum ALB, bilirubin,
PTA, abdominal ultrasonography and CTP score, and
alpha-fetoprotein and liver imaging were detected. Exclu-
sion criteria were presence of active moderate to severe
hepatic encephalopathy, spontaneous peritonitis or variceal
bleeding during 1 mouth before enrollment; refractory as-
cites; hemoglobin ≤ 7.0 g/L, platelet <300 000/ul; serum
Cr>2 mg/dL at screening; positive HIV or HCV antibody;
active thrombosis of the portal, hepatic or splenic veins;
hepatocellular carcinoma or other malignancies; active in-
fectious disease; evidences of active autoimmune liver dis-
ease (e.g. gamma globulin > twice normal, ALT > 3 times
normal in patients with autoimmune hepatitis); lines of
evidence of extrahepatic biliary disease (e.g. presence of
primary sclerosing cholangitis or bile duct stone); presence
of severe comorbid diseases (e.g. severe renal, respiratory,
or cardiac disease); history of alcohol or hepatotoxic drugs
use within the last 6 months before enrollment; unwilling
to assign the informed consent; death or missing before
endpoint of follow-up. All the patients enrolled first re-
ceived 1 week of routing medical treatment (baseline time
point), and then received the transplantation of autologous
BMSCs. The protocol of mobilized BMSCs transplantation
was described in our previous study [32]. Patients received
recombinant granulocyte-colony stimulating factor (G-
CSF) (Qi Lu Pharmaceutical Co. Ltd, Jinan, China) sub-
cutaneously at 5–10 μg/kg/day for 4 days to induce BMSCs
into peripheral blood. BMSCs were collected by means of
apheresis using the COBER Spectra™ Apheresis System
(Gambro BCT Inc., Stockholm, Sweden). When the num-
ber of BMSCs reached to 107–108/kg, 60 ml BMSCs were
returned to the patient via the hepatic artery in the imaging
department of our hospital. During our follow-up, enrolled
patients received regular anti-viral treatment and the virus
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characteristics of the enrolled patients were shown in
Table 3. The protocol for the clinical trial conformed to
the ethical guidelines of the Declaration of Helsinki and
the enrolled populations were recruited with ethics com-
mittee approved by Xijing Hospital of The Fourth Military
Medical University (Xi’an, China). Formal written informed
consent was obtained from each patient.Follow-up
All patients were followed up for more than 1 year dur-
ing this study. Clinical manifestation and physical exam-
ination were performed at 3-month intervals during the
follow-up. At each visit, the concentrations of serum
ALB, PTA, and CHE were measured to monitor the liver
function of patients. CTP and MELD scores were calcu-
lated to assess the kinetics of the liver function of pa-
tients. During our follow-up, enrolled patients received
regular anti-viral treatment and the virus load should be
under the limit of detection. If virologic breakthrough or
resistance occurred, “add on” or “switch to” another
effective anti-viral drug would be adopted in according
to guideline-recommend rescue measure. Venous blood
samples were collected from all enrolled patients at each
visit for the text of serum cytokines. The end of follow-
up was December 2011. Endpoint was defined as the
end of follow-up.Enzyme-linked immunosorbent assay (ELISA)
Serum levels of TNF-alpha, IFN-gamma, IL-12, IL-13,
IL-4, TGF-beta1, IL-17, and IL-8 in enrolled populations
were measured by ELISA kits (R&D Systems, Abingdon,
UK) according to the manufacturer’s instruction. All the
samples were assessed in duplicate. Plates were read using
the Thermofisher (Massachusetts, America) microplate
reader and cytokine concentration was calculated from











Values are expressed as the mean±standard deviation, number or
medians (range).
CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease.Animal studies
Animals and treatments
Male C57BL/6 mice (10 to 12 weeks old, 20 to 28 g) were
obtained from the animal center of the Fourth Military
Medical University (Xi’an, China). They were provided
food and water ad libitum and maintained on a 12-h light/
dark cycle. All animal experiments were performed in
accordance with guidelines from the Fourth Military Med-
ical University Institutional Animal Care and Use Com-
mittee. Animals were assigned to groups randomly and
we adopted a new procedure for inducing liver injury [33]
with slight modification. In brief, liver injury was induced
by intraperitoneal injection of 0.2 ml of a mixture of CCl4
and olive oil twice weekly for 6 weeks. The percentage
of CCl4 in the olive oil (v/v) was increased gradually
over time as follows: week 1, 13%; week 2, 16%; week 3,
20%; and weeks 4 to 6, 25%. Control mice received olive
oil only.
Bone marrow stem cells preparation
C57BL/6 mice were killed by CO2 asphyxia and their limbs
were removed for bone marrow isolation. The bone mar-
row was flushed from the femurs and tibias with serum-
free RPMI-1640 (Gibco BRL, Carlsbad, CA) medium using
25 G needle, filtrated and centrifuged at 400 g for 5 min.
For elimination of red blood cells, the cells were incubated
in an RBC lysis solution (Gibco BRL) for 3 min.
Examination of liver injury
Liver injury was determined by measuring serum ALB,
as well as H&E and Sirius red staining. The liver fibrosis
area was quantified with Sirius red staining as described
previously [34]. Briefly, the red areas with Sirius red stain-
ing were assessed at 100 ×magnification with a quantita-
tive image analyzer. The mean value of five randomly
selected areas per sample was used as the percentage of
fibrotic areas.
Measurement of IL-17 levels
The serum IL-17 levels were measured by ELISA using a
Ready-SET-GO! Mouse IL-17A kit from eBioscience (San
Diego, CA) according to the manufacturer’s instructions.
RT-PCR analysis
Total RNA was extracted from 50 mg fresh or frozen
liver tissues using RNA extraction kits from Takara Bio
(Otsu, Japan) according to the manufacturer’s instruc-
tions. RNA (1 μg) was reverse-transcribed to cDNA at
37°C for 15 minutes and 85°C for 15 seconds using
Superscript I kit (Takara Bio). Primers for alpha-SMA,
collagen-1 and beta-actin were predesigned and validated
by Takara. Primers were as follows: forward, 5′-AAGAG
CATCCGACACTGCTGAC-3′, reward, 5′-AGCACAGC
CTGAATAGCCACATAC-3′ (alpha-SMA); forward, 5′-G
Figure 6 The study design for the role of IL-17 in BMSCs-
mediated amelioration of liver injury. After 6 weeks of CCl4
administration to induced liver injury, the mice were randomly
divided into 5 groups and then were given a tail vein injection of
vehicle, a tail vein injection of BMSCs (5 × 106 cells in 0.2 ml PBS), a
intraperitoneal injection of rmIL-17, a intraperitoneal injection of
rmIL-17 and a tail vein injection of BMSCs, and five intraperitoneal
injections of anti-mouse IL-17 mAb, respectively (red arrowhead
showed the time point). Then the mice continued to be given CCl4
injection during our study to maintain liver fibrotic status. Black
arrowhead, the time of CCl4 administration; green arrowhead,
sacrificed time.





actin primer was used for internal control. RT-PCR was
performed using Express SYBR Green (Takara). All reac-
tions were performed in triplicate. Levels are expressed
relative to matched control samples from the same time
points. The specificity of the amplification products was
confirmed by ethidium bromide-stained 1.5% agarose gels.
The effect of IL-17 on the pathogenesis of liver injury
induced by CCl4 administration in mice
Monoclonal rat anti-mouse IL-17 antibody (anti-IL-17
mAb), rat IgG2a isotype and rmIL-17 were purchased from
R&D Systems (Abingdon, UK). On days −1, +1, +3, +5
and +7 after 6-week CCl4 administration, mice were
injected anti-IL-17 mAb intraperitoneally (100 μg of
anti-IL-17 mAb in 0.2 ml of sterile phosphate buffer so-
lution (PBS)) (five total injections) in non-fasting condi-
tion. As a control, rat IgG2a was administered. RmIL-17
was intraperitoneally injected (1 μg of rmIL-17 in 0.2 mlof sterile PBS containing 0.5% BSA) on day −1 after 6-
week CCl4 administration in nonfasting condition. As a
control, vehicle was administered. Mice were sacrificed
after 6 weeks of CCl4 administration.
The role of IL-17 in the therapeutic effect of homogeneous
BMSCs transplantation on CCl4-treated mice
As shown in Figure 6, after 6 weeks of CCl4 administra-
tion to induced liver injury, the mice were randomly di-
vided into several groups. Mice in BMSCs group were
given a tail vein injection of BMSCs (5 × 106 BMSCs in
0.2 ml PBS), in rmIL-17 group a intraperitoneal injection
of rmIL-17, in rmIL-17 + BMSCs group a intraperitoneal
injection of rmIL-17 and a tail vein injection of BMSCs,
and in anti-IL-17 mAb group five intraperitoneal injections
of anti-IL-17 mAb. The control groups were given vehicle,
or rat IgG2a injection. Then the mice continued to be
given CCl4 injection during our study to maintain liver fi-
brotic status. One group mice were only given CCl4 injec-
tion during the whole study and served as control. Mice
were sacrificed at the end of 10-week CCl4 administration.
Statistical analysis
Comparison between groups was analyzed by the Stu-
dent’s t test or ANOVA. The Spearman rank correlation
test was used for correlation analysis. Data are reported
as means ± standard deviation (SD). A p value lower than
0.05 was considered to be statistically significant. Statistical
analysis was performed by GraphPad Prism 5.0 (GraphPad
Software, Inc., La Jolla, CA) on a personal computer with
Windows 7 operating system.
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